Argent Biopharma Ltd
0.01
EUR
0.00
(0.00%)
ISIN
AU0000326647
Return %
Stock
S&P 500
1Y
-73.40
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Roby Reuven Zomer
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 295 Rokeby Road Subiaco WA Australia 6008
- IPO Date
- Nov 6, 2006
- Website
- mgcpharma.com.au
- Similar Companies
- Business
- Argent BioPharma Limited, a clinical-stage biopharmaceutical company focused on immunology and neurology therapeutics, develops and commercializes nano-engineered medicines with the aim of addressing unmet medical needs. The company’s principal product candidates include CannEpil, a cannabinoid-based therapy for refractory epilepsy and other neurological conditions; CimetrA (Cimetra), an anti-inflammatory agent targeting acute lung injury and related cytokine-driven disorders; and CogniCann, intended to improve quality of life for patients with dementia and Alzheimer’s disease. Argent BioPharma operates across multiple geographies, with activities and regulatory engagement in key markets, and pursues preclinical and translational programs such as Irnican for glioblastoma multiforme and RGAI03MW01 for chronic wound treatment, alongside ongoing collaborations to advance antimicrobial therapies and related wound-care solutions. The company previously traded as MGC Pharmaceuticals Limited before adopting the Argent BioPharma name, and it maintains a headquarters and primary operations in Australia, with subsidiary and partner footprints extending into Europe and other regions as part of its global development and commercialization strategy. Argent BioPharma's business model centers on research and development, clinical evaluation, regulatory pathways, and strategic partnerships to progress its pipeline toward potential commercialization, supported by ongoing partnerships and governance enhancements in the past two years to accelerate growth and pipeline progression. The company’s offerings encompass drug discovery, formulation, preclinical and clinical trial activities, regulatory strategy, and potential commercialization services, with a focus on bridging neurology and immunology through nano-engineered therapeutics. Founding year is 2014, with headquarters in Subiaco, Western Australia, and a strategic emphasis on expanding clinical development, international collaborations, and potential market entry in select jurisdictions as it advances CannEpil, CimetrA, and CogniCann along with its broader development portfolio.